We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

By LabMedica International staff writers
Posted on 06 Jun 2023
Print article
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels. These tests are essential in identifying type 1, type 2, and pre-diabetes, as well as managing ongoing diabetes. For diabetic individuals, monitoring HbA1c levels in the blood aids in the long-term tracking of blood glucose levels. The rising prevalence of diabetes and other lifestyle diseases is expected to drive the growth of the HbA1c testing devices market. Additionally, increased focus on preventive care and greater accuracy of HbA1c testing devices in diagnosing diabetes are expected to further contribute to market growth. However, the elevated cost of HbA1c laboratory testing may inhibit this growth. Hence, the global HbA1c testing devices market is projected to expand at a CAGR of 10.3%, from USD 1.72 billion in 2023 to USD 2.56 billion in 2027.

These are the latest findings of Research and Markets (Dublin, Ireland), a provider of market research reports and data.

The two main types of HbA1c testing devices are benchtop and handheld devices. Benchtop HbA1c testing devices, designed for ease of use on a laboratory bench, are utilized in laboratories to test patients' blood sugar levels. The advancement of HbA1c testing devices, such as point-of-care testing (POCT) and handheld devices, has simplified diabetes monitoring for both patients and healthcare professionals. These devices provide speedy and precise results, reducing reliance on conventional lab-based testing. The HbA1c testing devices market consists of automated, semi-automated, and bio-sensor-based instruments. The advent of cost-effective HbA1c tests and devices is expected to propel market growth. Various methods used to measure HbA1c include ion-exchange chromatography, electrophoretic methods, mass spectroscopy, reversed-phase HPLC, and electrospray iontophoresis, employed in hospitals, pharmaceuticals, medical devices, and laboratory testing.

The high rate of undiagnosed diabetes in emerging economies presents promising growth opportunities for the HbA1c testing devices market. Regionally, North America dominated the global HbA1c testing devices market in 2022. The growth of the HbA1c testing devices market in Europe is expected to be driven by increased product awareness and higher adoption of tests in countries such as Germany, France, and the UK. However, Asia-Pacific is projected to be the fastest-growing market for HbA1c testing devices during the forecast period, due to the evolving healthcare infrastructure in countries like China and India, as well as the rapidly rising incidence of diabetes in the region.

Related Links:
Research and Markets 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.